XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
 12 Months Ended
Jun. 30, 2023
Stock Settled Stock Appreciation Rights SARS [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock-Based Compensation Grant Details
In 2021, we granted SSSARs to various employees under the terms of the plan. The following table summarizes information relating to these grants:
2021
SSSARs granted124 
Weighted average grant date fair value per right$36.24 
Weighted average assumptions used in fair value calculations:
Risk-free interest rate0.51 %
Dividend yield1.69 %
Volatility factor of the expected market price of our common stock28.63 %
Expected life in years4.55
Compensation Expense And Tax Benefits Recorded
The following table summarizes our SSSARs compensation expense and tax benefits recorded for each of the years ended June 30:
202320222021
Compensation expense$1,972 $3,566 $3,568 
Tax benefits$216 $749 $749 
Intrinsic value of exercises$3,873 $317 $6,187 
Fair Value Of Awards Vested
The total fair values of SSSARs vested for each of the years ended June 30 were as follows:
202320222021
Fair value of vested rights$2,611 $4,095 $3,404 
Stock-Settled Stock Appreciation Rights Activity
The following table summarizes the activity relating to SSSARs granted under the plan for the year ended June 30, 2023:
Number of
Rights		Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life in
Years		Aggregate
Intrinsic
Value
Outstanding at beginning of year393 $158.12 
Exercised(225)$152.46 
Granted— $— 
Forfeited(13)$165.36 
Outstanding at end of year155 $165.77 2.15$5,463 
Exercisable and vested at end of year122 $162.57 2.01$4,709 
Vested and expected to vest at end of year155 $165.77 2.15$5,463 
Stock-Settled Stock Appreciation Rights Outstanding By Grant Year
The following table summarizes information about the SSSARs outstanding by grant year at June 30, 2023:
 OutstandingExercisable
   Weighted Average  
Grant YearsRange of
Exercise Prices		Number
Outstanding		Remaining
Contractual
Life in
Years		Exercise
Price		Number
Exercisable		Weighted
Average
Exercise
Price
2021
$167.18-$187.30
782.64$177.7945$177.76
2020
$153.71-$154.22
761.66$153.7176$153.71
2019
$154.48
10.66$154.481$154.48
Employee Restricted Stock [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock-Based Compensation Grant Details
In 2023, 2022 and 2021, we granted shares of restricted stock to various employees under the terms of the plan. The following table summarizes information relating to these grants:
202320222021
Employees
Restricted stock granted29 30 17 
Grant date fair value$4,448 $5,691 $2,918 
Weighted average grant date fair value per award$154.80 $189.12 $177.89 
Director Restricted Stock [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock-Based Compensation Grant Details
In 2023, 2022 and 2021, we also granted shares of restricted stock to our nonemployee directors under the terms of the plan. The following table summarizes information relating to each of these grants:
202320222021
Nonemployee directors
Restricted stock granted4 5 4 
Grant date fair value$919 $799 $774 
Weighted average grant date fair value per award$203.34 $162.15 $172.89 
Restricted Stock [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Compensation Expense And Tax Benefits Recorded
The following table summarizes our restricted stock compensation expense and tax benefits recorded for each of the years ended June 30:
202320222021
Compensation expense$4,432 $4,942 $3,558 
Tax benefits$677 $1,038 $747 
Fair Value Of Awards Vested
The total fair values of restricted stock vested for each of the years ended June 30 were as follows:
202320222021
Fair value of vested shares$4,996 $2,772 $3,148 
Restricted Stock Activity
The following table summarizes the activity relating to restricted stock granted under the plan for the year ended June 30, 2023:
Number of
Shares		Weighted
Average Grant
Date Fair Value
Unvested restricted stock at beginning of year74 $172.27 
Granted33 $161.40 
Vested(32)$156.89 
Forfeited(10)$171.29 
Unvested restricted stock at end of year65 $174.62 
Performance Units [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock-Based Compensation Grant Details
In 2023 and 2022, we granted performance units to various employees under the terms of the plan. The following table summarizes information relating to these grants:
20232022
Performance units granted26 20 
Grant date fair value$4,572 $4,151 
Weighted average grant date fair value per award$173.73 $201.67 
Compensation Expense And Tax Benefits Recorded
The following table summarizes our performance units compensation expense and tax benefits recorded for each of the years ended June 30:
20232022
Compensation expense$2,678 $1,055 
Tax benefits$355 $222 
Performance Units Grant Date Valuation Assumptions For our performance units with a market condition, the grant-date fair value is estimated using a Monte Carlo simulation. The assumptions used in the Monte Carlo simulation were as follows:
20232022
Risk-free interest rate3.18 %0.41 %
Dividend yield2.08 %1.65 %
Volatility factor of the expected market price of our common stock32.20 %31.30 %
Performance Units Activity
The following table summarizes the activity relating to performance units granted under the plan for the year ended June 30, 2023:
Number of
Units		Weighted
Average Grant
Date Fair Value
Unvested performance units at beginning of year19 $201.65 
Granted26 $173.73 
Vested— $— 
Forfeited(5)$186.60 
Unvested performance units at end of year40 $185.39